Expanded access treatment for chronic lower back pain
Part of Bones, joints & muscles, Pain clinical trials.
This program provides access to an investigational cell therapy for people with chronic lower back pain caused by degenerative disc disease, when no other satisfactory treatment options are available. The goal is to evaluate the treatment's safety and potential benefit in a real-world setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with chronic lower back pain due to degenerative disc disease.
- You have tried other treatments that did not work or are not suitable for you.
- You are not able to join the main clinical trial for this treatment.
- You do not have any medical condition that would make the treatment unsafe.
- You are not allergic to any part of the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial gives people with serious diseases access to a special cell therapy (a treatment made from your own immune cells) when they have no other options. It's a 'compassionate use' program, meaning the drug is available outside of a clinical trial if you meet certain conditions.
This trial provides access to a CAR T-cell therapy (ide-cel) that was made for you but didn't meet commercial release standards. It's an expanded access program for patients who have no other options and are stable enough to receive the treatment.
This trial offers compassionate use of the gene therapy ZVS101e for people with Bietti crystalline dystrophy (BCD) who were in the control group of an earlier study. It aims to give extended treatment access to those who didn't receive the experimental therapy before.
This trial tests a new oral drug called DZD8586 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if it can help control the disease.
This program provides access to an investigational drug for people who have already been part of the main clinical trial and have no other treatment options. It aims to give continued treatment when regular access is not possible.
This program provides access to an investigational medicine called del-zota (also known as AOC 1044) for people with Duchenne muscular dystrophy (DMD) whose genetic mutation can be treated by exon 44 skipping. The medicine aims to help the body produce a shorter but functional version of the dystrophin protein, which may slow muscle damage and improve function.
Hear when a new Chronic Back Pain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.